These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 30075835)

  • 1. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
    Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy.
    De Mattia E; Bignucolo A; Toffoli G; Cecchin E
    Curr Med Chem; 2020; 27(25):4249-4273. PubMed ID: 31298142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Madi A; Fisher D; Maughan TS; Colley JP; Meade AM; Maynard J; Humphreys V; Wasan H; Adams RA; Idziaszczyk S; Harris R; Kaplan RS; Cheadle JP
    Eur J Cancer; 2018 Oct; 102():31-39. PubMed ID: 30114658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized treatment for patients with colorectal cancer: role of biomarkers.
    Duffy MJ
    Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
    Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
    Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.
    Bignucolo A; De Mattia E; Cecchin E; Roncato R; Toffoli G
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28708103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.
    Abdullah-Koolmees H; van Keulen AM; Nijenhuis M; Deneer VHM
    Front Pharmacol; 2020; 11():595219. PubMed ID: 33568995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.
    Panczyk M
    World J Gastroenterol; 2014 Aug; 20(29):9775-827. PubMed ID: 25110414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments.
    Bruera G; Ricevuto E;
    Pharmgenomics Pers Med; 2020; 13():601-617. PubMed ID: 33235483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
    Tan BR; McLeod HL
    Semin Oncol; 2005 Feb; 32(1):113-9. PubMed ID: 15726513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
    De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
    Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.
    Manson LE; van der Wouden CH; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2017 Jul; 18(11):1041-1045. PubMed ID: 28685652
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacogenomics and Personalized Medicine.
    Cecchin E; Stocco G
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients.
    Qin W; Du Z; Xiao J; Duan H; Shu Q; Li H
    Pharmacogenomics; 2020 Feb; 21(3):209-219. PubMed ID: 31967514
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
    Cortejoso L; López-Fernández LA
    Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic markers in methotrexate treatments.
    Giletti A; Esperon P
    Pharmacogenomics J; 2018 Dec; 18(6):689-703. PubMed ID: 30237581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.